• Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 303.59 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.23
▼ -0.12 (-5.11%)

This chart shows the closing price for CELU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celularity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CELU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CELU

Analyst Price Target is $9.00
▲ +303.59% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Celularity in the last 3 months. The average price target is $9.00, with a high forecast of $15.00 and a low forecast of $5.00. The average price target represents a 303.59% upside from the last price of $2.23.

This chart shows the closing price for CELU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Celularity. This rating has held steady since June 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2022Morgan StanleyLower TargetEqual Weight$8.00 ➝ $5.00Low
8/25/2022Alliance Global PartnersInitiated CoverageBuy$15.00Low
8/23/2022Truist FinancialLower TargetHold$10.00 ➝ $6.00Low
6/22/2022HC WainwrightInitiated CoverageBuyLow
4/6/2022Truist FinancialDowngradeBuy ➝ Hold$10.00High
4/1/2022OppenheimerBoost Target$9.00 ➝ $10.00Low
1/27/2022OppenheimerInitiated CoverageOutperform$9.00Medium
11/24/2021Morgan StanleyInitiated CoverageEqual Weight$9.00Medium
10/19/2021Truist FinancialInitiated CoverageBuy$12.00Medium
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.29 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/9/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/8/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
7/7/2022
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/5/2022
  • 4 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
10/5/2022

Current Sentiment

  • 4 very positive mentions
  • 19 positive mentions
  • 2 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Celularity logo
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.
Read More

Today's Range

Now: $2.23
Low: $2.18
High: $2.35

50 Day Range

MA: $2.73
Low: $2.12
High: $3.25

52 Week Range

Now: $2.23
Low: $1.95
High: $13.19

Volume

13,254 shs

Average Volume

1,242,222 shs

Market Capitalization

$308.43 million

P/E Ratio

10.62

Dividend Yield

N/A

Beta

0.29

Frequently Asked Questions

What sell-side analysts currently cover shares of Celularity?

The following sell-side analysts have issued reports on Celularity in the last twelve months: Alliance Global Partners, HC Wainwright, Morgan Stanley, Oppenheimer Holdings Inc., and Truist Financial Co..
View the latest analyst ratings for CELU.

What is the current price target for Celularity?

4 Wall Street analysts have set twelve-month price targets for Celularity in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 303.6%. Alliance Global Partners has the highest price target set, predicting CELU will reach $15.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $5.00 for Celularity in the next year.
View the latest price targets for CELU.

What is the current consensus analyst rating for Celularity?

Celularity currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CELU will outperform the market and that investors should add to their positions of Celularity.
View the latest ratings for CELU.

What other companies compete with Celularity?

How do I contact Celularity's investor relations team?

Celularity's physical mailing address is 1325 AVENUE OF THE AMERICAS 25TH FLOOR, NEW YORK NY, 10019. The company's listed phone number is 908-768-2170. The official website for Celularity is www.celularity.com. Learn More about contacing Celularity investor relations.